ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: physical function

What’s New in Psoriatic Arthritis?

David Pisetsky, MD, PhD  |  October 28, 2025

Dr. David Pisetsky curated the research presented at ACR Convergence 2025 and answers the question “What new research on psoriatic arthritis has the potential to impact patient care or future research?”

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2025ACR Convergence 2025 - PsAAxial Psoriatic Arthritis (axPsA)inflammatory bowel disease (IBD)Obesity

Let’s Discuss: Insights from the ACR Convergence 2025 Review Course

Jason Liebowitz, MD, FACR  |  October 27, 2025

The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.

Filed under:ACR ConvergenceMeeting ReportsOther Rheumatic ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2025ACR Convergence 2025 - LNdrugInflammatory Brain DiseasesInflammatory MyopathiesLupusLupus nephritisRheumatic Diseasesystemic lupus erythematosus (SLE)

A New Treatment for Fibromyalgia?

Michele B. Kaufman, PharmD, BCGP  |  September 11, 2025

The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.

Filed under:ConditionsDrug UpdatesPain Syndromes Tagged with:Chronic paincyclobenzaprine HCl tabletFDA approvalFibromyalgiaTonmyaU.S. Food and Drug Administration (FDA)

Guidelines for ILD in Systemic Autoimmune Rheumatic Disease

Ruth Jessen Hickman, MD  |  August 26, 2025

Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Sclero­derma Program, notes that more recent studies have increased our awareness…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceSjögren’s DiseaseSystemic Sclerosis Tagged with:Interstitial Lung Diseaseinterstitial lung disease (ILD)Sjögren’s Disease supplement

Case Report: Pulmonary Artery Stenosis Secondary to Granulomatosis with Polyangiitis

Sambhawana Bhandari, MD, & Colin Diffie, MD  |  August 7, 2025

This report presents a rare case of bilateral pulmonary artery stenosis secondary to granulomatosis with polyangiitis, underscoring the importance of recognizing large-vessel involvement as a potential manifestation of AAV; it also includes a narrative review analyzing eight previously reported cases.

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumANCA-Associated Vasculitiscase reportFellows Forumgranulomatosis with polyangiitislarge-vessel vasculitisPulmonary Artery StenosisPulmonary Artery Stentingpulmonary hypertension

A Joint Doctor with Joint Disease

Samantha C. Shapiro, MD  |  July 31, 2025

This year, Dr. Sam Shapiro underwent total hip arthroplasty. Her journey from being an athlete to suffering from arthritis and chronic joint pain was difficult. Here is her story, complete with post-op insights.

Filed under:ConditionsOpinionOsteoarthritis and Bone DisordersPatient Perspective Tagged with:hip osteoarthritsJoint Surgerypatient perspectivePhysical Therapy

Rheumatology in China: An American Fellow’s Experience

Audrey Liu, MD  |  July 9, 2025

An American rheumatology fellow explores the differences& similarities between the U.S. & Chinese health systems through a visit toa hospital inHangzhou, China.

Filed under:OpinionPractice Support Tagged with:Access to carecost of health careFellowsFellows Forumglobal healthhealthcare policyhealthcare systems comparisonmedical educationrheumatology in China

New Analysis Reveals More Potential Contributors to Takayasu Arteritis

Bryn Nelson, PhD  |  June 8, 2025

Recent research led to development of a cumulative genetic risk score for Takayasu arteritis, identifying differing susceptibility between groups with different genetic ancestries.

Filed under:ConditionsResearch RheumVasculitis Tagged with:genetic susceptibilitygeneticsHLA-B*52large-vessel vasculitispatient communicationphysician-patient communicationPrecision MedicineTakayasu arteritistherapeutic targets

Abatacept Shows Promise for Some Myositis Patients

Deborah Levenson  |  May 12, 2025

Injected abatacept may be a worthwhile treatment for certain patients with idiopathic inflammatory myositis (IIM), according to recent research.1 Patients with the rare autoimmune conditions involving inflammation of muscle (myositis) and other organ systems suffer widespread organ dysfunction, increased morbidity, physical disabilities and early death. Symptoms vary by subtype. For example, dermatomyositis (DM) involves muscle…

Filed under:Biologics/DMARDsConditionsDrug UpdatesMyositisResearch Rheum Tagged with:abataceptAC&Ridiopathic inflammatory myositis

Semaglutatide for Patients with Knee Osteoarthritis?

Bryn Nelson, PhD  |  April 8, 2025

Based on decades of data from dietary and other lifestyle interventions, doctors have long known that significant weight loss can be an effective treatment for people who are overweight and have knee osteoarthritis (OA). One meta-analysis showed that OA pain, function and stiffness scores improved by 2% for every 1% in lost weight.1 But the…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:knee osteoarthritisResearch Reviewresearch reviewssemaglutideweight loss

  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 82
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences